Navigation Links
Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians
Date:11/9/2011

MIAMI BEACH, Fla., Nov. 9, 2011 /PRNewswire/ -- Biotech developer Divine Skin Inc. (OTC Bulletin Board: DSKX) which has been expanding the topical hair-growth segment, is rolling out that market's newest, most potent, only customizable system, Polaris API Solution 9, to be supplied by physicians for treatment through multiple methods of action.

With well-established materials like minoxidil sulfate, finasteride, alfatradiol, and other active ingredients, Polaris API Solution 9 is the most complete solution that can be used for hair loss, either by prescription or over the counter configured to the individual needs of the patient by physicians. The current sales leader contains only 5% minoxidil in a standard carrier.

"We are launching a new category," declared CEO Daniel Khesin, speaking on a conference call with investors. "We expect this line to change the game and to offer a powerful new tool for dermatologists that can really make a difference in their approach to treatment."

Half of all men will experience some hair loss by age 50, and they can only purchase the customized Polaris product through physicians, who can create the potent mix of active pharmaceutical ingredients (API).

Divine Skin, which posted revenue of $5.4 million in 2010 — up 55 percent over the previous year — creates a major new revenue stream with Polaris API Solution 9, and stockholders expect to benefit for several years.

In published clinical trials, each major component of the new API — minoxidil sulfate, finasteride, and alfatradiol — has proven to inhibit androgenic alopecia (male pattern baldness) effectively. The system also includes other auxiliary agents like apple polyphenol, copper peptides, nutrients, and conditioners to enhance the formula further.

"With very few options available," says Khesin, "Polaris API Solution 9 is by far the most viable option for physicians to quickly and easily customize the ideal treatment for their patients. We expect everyone to do very well with this product."

Besides hair growth, Divine Skin with a strong focus on personal care science and innovation, markets premium topical solutions and drugs with more than 60 SKUs. In the United States, revenue to all manufacturers of all pharmaceutical preparations acting on the skin totaled $3.8 billion in 2009, according to the US Census Bureau. Divine Skin now sells in more than 20 countries.

About Divine Skin

Divine Skin Inc. leads in the development of biotechnology for topical, nutritional, and pharmaceutical therapies. It markets worldwide through online and specialty retailers, cosmetics wholesalers, salons, and medical offices. The fast-growing company went public in 2009.

DS Laboratories, its flagship brand, offers high-performance topical solutions to restore growth and radiance to hair, suppress dandruff and unwanted hair, control acne, improve hygiene, and reduce cellulite and wrinkles. Bioavailability is enhanced through encapsulation (www.dslaboratories.com).

The Sigma Skin brand sells through upscale retailers like Neiman Marcus in the United States and Harvey Nichols in the United Kingdom. The topical products address hair loss and other signs of aging (www.sigmaskin.com).

Polaris Research Laboratories makes high-potency minoxidil-based hair-growth formulas (www.polarisresearchlabs.com).

The Pure Guild offers purity with performance: Botanical compounds proven effective in clinical trials are extracted without industrial solvents or damaging heat and are sold through premium retailers (www.thepureguild.com).

NutraOrigin blends nutritional supplements that address the health concerns expressed by consumers, including fatigue, headache, obesity, mobility, menopause, erectile dysfunction, and others. In clinical trials for the US government, its Omega line proved to enhance mental function (www.nutraorigin.com).

Contact:
Abner Silva
Investor Relations
Divine Skin Inc.
1.407.342.4112
investors@divineskin.com


'/>"/>
SOURCE Divine Skin Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Divine Skin Posts Record Sales for 2010: Up 55% Over 2009
2. Divine Skin Announces Four Deals for Explosive Distribution Growth
3. First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin
4. Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX)
5. Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil
6. Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010
7. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
8. Rice rolls out new nanocars
9. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
10. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
11. Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery and ... today the appointment of a new Chairman, Mr John ... , effective immediately. James Garner , has ... Director and former Acting CEO, Mr Iain Ross , ... Director. --> James Garner , has also been ...
(Date:2/4/2016)... , ... February 04, 2016 , ... ... GC-MS and triple quad LC-MS, host live demos and poster sessions, and present ... and exhibition. The conference takes place March 6 to 10 at the Georgia ...
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
(Date:2/4/2016)... 4, 2016 Sinovac Biotech Ltd. ("Sinovac" or ... of biopharmaceutical products in China , ... of directors received on February 4, 2016 a preliminary ... consortium comprised of PKU V-Ming ( Shanghai ... CICC Qianhai Development ( Shenzhen ) Fund ...
Breaking Biology Technology:
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... solutions, today announced that its ClearPad ® TouchView ... products won two separate categories in the 8 th ... and Best Technology Breakthrough. The Synaptics ® TDDI ... simplified supply chain, thinner devices, brighter displays and borderless ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 /PRNewswire/ ... sensor-based diagnostic products, today announced the closing of a $9 ... investors.  Proceeds from the financing will be used to accelerate ... device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has been ...
Breaking Biology News(10 mins):